Trial Profile
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Early breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium
- 30 Jun 2012 Planned number of patients changed from 300 to 330 as reported by European Clinical Trials Database.
- 21 Jan 2011 New source identified and integrated (Clinical Trials Registry - India).